Oak S, Karajgikar O, Teni T. Curcumin mediates selective aggregation of mutant p53 in cancer cells: A promising therapeutic strategy. Biochem Biophys Res Commun. 2023;677:141-148 pubmed publisher

Iwahashi N, Ikezaki M, Komohara Y, Fujiwara Y, Noguchi T, Nishioka K, et al. Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis. PNAS Nexus. 2022;1:pgac128 pubmed publisher

Palanikumar L, Karpauskaite L, Al Sayegh M, Chehade I, Alam M, Hassan S, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12:3962 pubmed publisher

Tong X, Xu D, Mishra R, Jones R, Sun L, Schiltz G, et al. Identification of a druggable protein-protein interaction site between mutant p53 and its stabilizing chaperone DNAJA1. J Biol Chem. 2021;296:100098 pubmed publisher

Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, et al. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells. FEBS Open Bio. 2020;10:535-545 pubmed publisher

Xu D, Tong X, Sun L, Li H, Jones R, Liao J, et al. Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53. Mol Carcinog. 2019;58:2052-2064 pubmed publisher

Aggarwal M, Saxena R, Asif N, Sinclair E, Tan J, Cruz I, et al. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition. J Exp Clin Cancer Res. 2019;38:307 pubmed publisher

Dabiri Y, Abu El Maaty M, Chan H, Wölker J, Ott I, Wolfl S, et al. p53-Dependent Anti-Proliferative and Pro-Apoptotic Effects of a Gold(I) N-Heterocyclic Carbene (NHC) Complex in Colorectal Cancer Cells. Front Oncol. 2019;9:438 pubmed publisher

Yang Hartwich Y, Tedja R, Roberts C, Goodner Bingham J, Cardenas C, Gurea M, et al. p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Mol Cancer Res. 2019;17:153-164 pubmed publisher

Mircetic J, Dietrich A, Paszkowski Rogacz M, Krause M, Buchholz F. Development of a genetic sensor that eliminates p53 deficient cells. Nat Commun. 2017;8:1463 pubmed publisher

Wang H, Wang Y, Wu D, Hung C, Chen C, Lee H. Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer. Tumour Biol. 2017;39:1010428317694316 pubmed publisher

Ota A, Nakao H, Sawada Y, Karnan S, Wahiduzzaman M, Inoue T, et al. ?40p53? suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells. J Cell Sci. 2017;130:614-625 pubmed publisher

Morton D, Patel D, Joshi J, Hunt A, Knowell A, Chaudhary J. ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation. Oncotarget. 2017;8:2536-2549 pubmed publisher

Bado I, Nikolos F, Rajapaksa G, Gustafsson J, Thomas C. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Oncotarget. 2016;7:13599-611 pubmed publisher

Park E, Lee J, Park J, Bang S, Yi S, Kim B, et al. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 2015;6:e1964 pubmed publisher

Chung J, Larsen A, Chen E, Bunz F. A PTCH1 homolog transcriptionally activated by p53 suppresses Hedgehog signaling. J Biol Chem. 2014;289:33020-31 pubmed publisher

Labrie M, Vladoiu M, Grosset A, Gaboury L, St Pierre Y. Expression and functions of galectin-7 in ovarian cancer. Oncotarget. 2014;5:7705-21 pubmed

Campion C, Labrie M, Lavoie G, St Pierre Y. Expression of galectin-7 is induced in breast cancer cells by mutant p53. PLoS ONE. 2013;8:e72468 pubmed publisher

Van Meter M, Mao Z, Gorbunova V, Seluanov A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle. 2011;10:3153-8 pubmed

Sauer L, Gitenay D, Vo C, Baron V. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene. 2010;29:2628-37 pubmed publisher

Baker S, Markowitz S, Fearon E, Willson J, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912-5 pubmed